OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Forecast, Price & News $0.09 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.07▼$0.1852-Week Range$0.07▼$0.48VolumeN/AAverage Volume5,341 shsMarket Capitalization$3.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About Sigyn Therapeutics (OTCMKTS:SIGY) StockSigyn Therapeutics, Inc. is a development-stage company, which focuses on creating therapeutic solutions that address unmet needs in global health. Its product, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. The company was founded by James A. Joyce and Craig P. Roberts on October 19, 2019 and is headquartered in San Diego, CA.Read More Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SIGY Stock News HeadlinesJune 3, 2023 | americanbankingnews.comReviewing Bioventus (NYSE:BVS) and Sigyn Therapeutics (OTCMKTS:SIGY)May 22, 2023 | fool.comBeam Therapeutics (NASDAQ: BEAM)June 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 17, 2023 | finance.yahoo.comSigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark ApplicationMay 16, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Reports First Quarter 2023 Financial ResultsMay 16, 2023 | finance.yahoo.comSigyn Therapeutics Reports First Quarter 2023 Financial ResultsApril 15, 2023 | americanbankingnews.comSigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest UpdateApril 11, 2023 | finance.yahoo.comSigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific OfficerJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.March 31, 2023 | finance.yahoo.comSigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-KMarch 21, 2023 | forbes.comChinook TherapeuticsFebruary 25, 2023 | seekingalpha.comJounce Therapeutics downgraded to market perform at Raymond James on company restructuringSee More Headlines SIGY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIGY Company Calendar Last Earnings5/16/2023Today6/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SIGY CUSIPN/A CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,930,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-820.79% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.82Miscellaneous Outstanding Shares38,264,000Free Float8,242,000Market Cap$3.48 million OptionableNot Optionable Beta-1.44 Key ExecutivesJames A. JoyceChairman & Chief Executive OfficerCharlene R. OwenDirector-OperationsJeremy Lee FerrellChief Financial OfficerCraig P. RobertsDirector & Chief Technology OfficerEric LynamDirector-Clinical AffairsKey CompetitorsArch TherapeuticsOTCMKTS:ARTHInVivo TherapeuticsNASDAQ:NVIVINVO BioscienceNASDAQ:INVODynatronicsNASDAQ:DYNTEKIMASOTCMKTS:ASNBView All Competitors SIGY Stock - Frequently Asked Questions How have SIGY shares performed in 2023? Sigyn Therapeutics' stock was trading at $0.17 at the start of the year. Since then, SIGY stock has decreased by 46.5% and is now trading at $0.0910. View the best growth stocks for 2023 here. How were Sigyn Therapeutics' earnings last quarter? Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) posted its quarterly earnings results on Tuesday, May, 16th. The company reported ($0.03) EPS for the quarter. What is Sigyn Therapeutics' stock symbol? Sigyn Therapeutics trades on the OTCMKTS under the ticker symbol "SIGY." How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sigyn Therapeutics' stock price today? One share of SIGY stock can currently be purchased for approximately $0.09. How much money does Sigyn Therapeutics make? Sigyn Therapeutics (OTCMKTS:SIGY) has a market capitalization of $3.48 million. How can I contact Sigyn Therapeutics? Sigyn Therapeutics' mailing address is 2468 Historic Decatur Road Ste. 140, San Diego CA, 92106. The official website for the company is www.sigyntherapeutics.com. The company can be reached via phone at (619) 353-0800 or via email at stephen@sigyntherapeutics.com. This page (OTCMKTS:SIGY) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.